📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Challenges in estimating the counterfactual placebo HIV incidence rate from a registration cohort: The PrEPVacc trial (2024)

First Author: Kansiime Sheila

Attributed to: Blood borne viruses funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1177/17407745241304721

Publication URI: http://dx.doi.org/10.1177/17407745241304721

Type: Journal Article/Review

Parent Publication: CLINICAL TRIALS

ISSN: 1740-7745